New Delhi: Plagued by allegations of lack of transparency, the government has decided to constitute an Inter Departmental Committee(IDC) to institutionalize a robust mechanism to ensure economy, efficiency, effectiveness and transparency in the arena of Pharmaceutical research.
The move came in pursuance of 46th Report of the Standing Committee on Chemicals and Fertilizers (Department of Pharmaceuticals) in respect of “Promotion and Coordination of basic applied and other research in areas related to the Pharmaceuticals Sector.”
The report recommended the constitution of a separate Inter-Departmental Committee in the arena of the Pharmaceutical sector to be headed by Secretary(Pharma). The objectives of the newly constituted IDC is to periodically review and coordinate research in a collaborative, synchronized and synergized way. This would allow optimum utilization of funds allocated for the purpose and to ensure no overlapping and duplication of efforts and resources.
The Inter-Departmental Committee (IDC) would comprise of the eleven members. The Committee may also co-opt experts from other Government Departments /Ministries /Organizations/Pharma Associations as and when required.
|1.||Secretary, Department of Pharmaceuticals||Chairperson|
|2.||Representative of Department of Health & Family Welfare not below the rank of Joint Secretary||Member|
|3.||Representative of Department of Health Research not below the rank of Joint Secretary||Member|
|4.||Representative of Department of Science and
Technology not below the rank of Joint Secretary
|5.||Representative of Department of Biotechnology not below the rank of Joint Secretary||Member|
|6.||Representative of Ministry of AYUSH not below the rank of Joint Secretary||Member|
|7.||Representative of Indian Council for Medical Research (ICMR) not below the rank of Joint Secretary||Member|
|8.||Representative of Council for Scientific and Industrial Research (CSIR) not below the rank of Joint Secretary||Member|
|9.||Representative of Department of Higher Education not below the rank of Joint Secretary||Member|
|10.||Joint Secretary(NIPER), Department of Pharmaceuticals||Member|
|11.||Joint Secretary(Policy),Department of Pharmaceuticals||Member &
Latest posts by Farhat Nasim (see all)
- Glenmark Pharma gets USFDA approval for generic version of VAGIFEM - April 25, 2019
- Monarch eTNS: First medical device for treating ADHD gets USFDA approval - April 25, 2019
- Indoco Remedies: USFDA retains OAI status for Goa plant - April 25, 2019